Risk of comorbidity in patients with multiple sclerosis: a nationwide cohort study in Sweden

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: (id:"swepub:oai:DiVA.org:oru-77224") > Risk of comorbidity...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Piehl, F.Department of Neurology, Karolinska University Hospital, Solna, Sweden (author)

Risk of comorbidity in patients with multiple sclerosis : a nationwide cohort study in Sweden

Article/chapterEnglish2019

Publisher, publication year, extent ...

Sage Publications,2019
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:oru-77224
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-77224URI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:vet swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Funding Agency:Celgene Corporation
Introduction: Substantial progress in the treatment of multiple sclerosis (MS) has been made since the 1990s. However, the presence of comorbidity and the impact of treatment are less defined. Here we determined rates of comorbidity before and after MS diagnosis as compared with a matched MS-free population.Methods: A national incident MS cohort diagnosed in 2008-2016 was identified in the Swedish National Patient Register with data further linked to the national Prescribed Drug Register and Cause of Death Register. In addition, a sub-cohort of MS patients was identified in the electronic medical records (EMR) of the Karolinska University Hospital. MS patients were matched with and compared to 10 MS-free individuals by age, sex, and region of residence. Incidence rates (IR) per 10,000 person-years and incidence rate ratios (IRR) of comorbidities were calculated after MS diagnosis.Results: In total, 6,602 MS patients were identified in the national cohort and were compared with 61,828 MS-free controls (female, 69%; median age, 40 years), while a sub-cohort from one hospital of 1,289 patients had a MS diagnosis recorded in EMR and was compared with 11,721 individuals without MS (female, 68%; median age, 37 years). The national MS cohort had higher proportions before MS diag-nosis compared with MS-free controls of autoimmune disease (1.3% vs 0.7%), bladder dysfunction (1.2% vs 0.2%), retinal disorders (2.4% vs 1.2%) and epilepsy (1.5% vs 0.8%). Similar patterns were observed for the single-hospital cohort, except for epilepsy. Bipolar disorder was more common among single-hospital MS patients (1.6% vs 0.7%).After MS diagnosis, patients in the national cohort had higher IR compared with MS-free controls of autoimmune disease (IRR 3.60; 95% confidence interval [CI], 2.88-4.51), bladder dysfunction (IRR 47.44; 95% CI, 36.81-61.14) and epilepsy (IRR 2.36; 95% CI, 1.75-3.17). Similar patterns were observed in the single-hospital cohort. Toxic liver disease was higher (IRR 3.51; 95% CI 1.37-8.98) in the MS cohort in the national cohort only, while bipolar disorder was higher only in the single-hospital cohort (IRR 1.88; 95% CI 1.10-3.22).Conclusions: Before a diagnosis of MS, patients already displayed an increased rate of comorbidity compared with MS-free controls. After diagnosis, patients with MS continued to display increased risk of several comorbidities, some of which may be explained by surveillance bias due to more frequent contact with healthcare.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Neurologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Neurology hsv//eng

Added entries (persons, corporate bodies, meetings, titles ...)

Castelo-Branco, A.Real-World Insights, IQVIA Nordics, Solna, Sweden (author)
Chiesa, F.Real-World Insights, IQVIA Nordics, Solna, Sweden (author)
Conte, S.Real-World Insights, IQVIA Nordics, Solna, Sweden (author)
Rosenlund, M.Real-World Insights, IQVIA Nordics, Solna, Sweden (author)
Lee, S.Celgene Corporation, Summit NJ, United States (author)
Minton, N.Celgene Corporation, Summit NJ, United States (author)
Niemcryk, S.Celgene Corporation, Summit NJ, United States (author)
Lindholm, A.Celgene Corporation, Summit NJ, United States (author)
Montgomery, Scott,1961-Örebro universitet,Institutionen för medicinska vetenskaper,Clinical Epidemiology and Biostatistics, Örebro University Hospital and Örebro University, Örebro, Sweden; Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden; Department of Epidemiology and Public Health, University College London, London, United Kingdom(Swepub:oru)smy (author)
Department of Neurology, Karolinska University Hospital, Solna, SwedenReal-World Insights, IQVIA Nordics, Solna, Sweden (creator_code:org_t)

Related titles

In:Multiple Sclerosis Journal: Sage Publications25:Suppl. 2, s. 102-1021352-45851477-0970

Internet link

https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-77224

Find in a library

Multiple Sclerosis Journal (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Piehl, F.; Castelo-Branco, ...; Chiesa, F.; Conte, S.; Rosenlund, M.; Lee, S.; show more...; Minton, N.; Niemcryk, S.; Lindholm, A.; Montgomery, Scot ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Neurology

Articles in the publication: Multiple Scleros ...

By the university: Örebro University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se